XBiotech Inc. Files Q2 2024 10-Q

TL;DR

XBiotech Q2 10-Q filed. Check financials.

AI Summary

XBiotech Inc. filed its 10-Q for the period ending June 30, 2024. The company, located in Austin, TX, operates in the pharmaceutical preparations sector. Financial details and operational updates for the second quarter of 2024 are presented in this filing.

Why It Matters

This filing provides investors and analysts with the latest financial performance and operational status of XBiotech Inc. for the second quarter of 2024.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, XBiotech faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 20240630 — Reporting Period End Date (Indicates the end of the fiscal quarter covered by the report.)
• 20240812 — Filing Date (The date the 10-Q was officially submitted to the SEC.)

Key Players & Entities

• XBiotech Inc. (company) — Filer of the 10-Q
• 20240630 (date) — End of the reporting period
• 20240812 (date) — Filing date
• Austin, TX (location) — Company headquarters
• 512-386-2900 (phone_number) — Company business phone

FAQ

Filing Documents

• xbit20240630_10q.htm (10-Q) — 706KB
• ex_708677.htm (EX-31.1) — 13KB
• ex_708678.htm (EX-31.2) — 13KB
• ex_708679.htm (EX-32.1) — 10KB
• 0001171843-24-004689.txt ( ) — 3287KB
• xbit-20240630.xsd (EX-101.SCH) — 26KB
• xbit-20240630_def.xml (EX-101.DEF) — 193KB
• xbit-20240630_lab.xml (EX-101.LAB) — 194KB
• xbit-20240630_pre.xml (EX-101.PRE) — 214KB
• xbit-20240630_cal.xml (EX-101.CAL) — 24KB
• xbit20240630_10q_htm.xml (XML) — 406KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements 6 Condensed Consolidated Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023 6 Condensed Consolidated Statements of Operations for the Three Months and Six Months Ended June 30, 2024 (unaudited) and 2023 (unaudited) 7 Condensed Consolidated Statements of Comprehensive Loss for the Three Months and Six Months Ended June 30, 2024 (unaudited) and 2023 (unaudited) 8 Condensed Consolidated Statements of Changes in Shareholders' Equity for the Three Months and Six Months Ended June 30, 2024 (unaudited) and 2023 (unaudited) 9 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 (unaudited) and 2023 (unaudited) 11 Notes to Condensed Consolidated Financial Statements (unaudited) 12 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 24 Item 4.

Controls and Procedures

Controls and Procedures 24

— OTHER INFORMATION

PART II — OTHER INFORMATION Item 1.

Risk Factors

Risk Factors 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25 Item 3. Defaults Upon Senior Securities 25 Item 4. Mine Safety Disclosures 25 Item 5. Other Information 25 Item 6. Exhibits 25

SIGNATURES

SIGNATURES 3 CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements, which reflect our current views with respect to, among other things, our operations and financial performance. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. You can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These forward-looking statements include, but are not limited to statements about: our ability to obtain regulatory approval to market and sell our product candidates in the United States, Europe and elsewhere; the initiation, timing, cost, progress and success of our research and development programs, preclinical studies and clinical trials for our product candidates; our ability to advance product candidates into, and successfully complete, clinical trials; our ability to successfully commercialize the sale of our product candidates in the United States, Europe and elsewhere; our ability to recruit sufficient numbers of patients for our future clinical trials for our pharmaceutical products; our ability to achieve profitability; the implementation of our business model and strategic plans; our ability to develop and commercialize product candidates for orphan and niche indications independently; our commercialization, marketing and manufacturing capabilities and s

View Full Filing

View this 10-Q filing on SEC EDGAR